8-K
filed February 22, 2023, 6:59 PM ET
ticker IART
CIK 0000917520
earnings
confidence high
sentiment neutral
materiality 0.60
Integra LifeSciences Q4 adj EPS $0.94, rev $398M; FY2023 guidance rev $1.60-1.62B, adj EPS $3.43-3.51
INTEGRA LIFESCIENCES HOLDINGS CORP
2022-FY EPS reported
$2.16
revenue$1,557,666,000
- Q4 2022 revenues $398.0M (-1.8% reported, +2.9% organic); GAAP EPS $0.63, adj EPS $0.94.
- Full-year 2022 revenues $1,557.7M (+1.0% reported, +4.2% organic); GAAP EPS $2.16, adj EPS $3.36.
- FY2023 guidance: revenues $1,602M-$1,620M (organic growth 4.0%-5.2%), adj EPS $3.43-$3.51.
- Entered $150M accelerated share repurchase agreement with Goldman Sachs, expected to complete in H1 2023.
- Codman Specialty Surgical organic growth 1.8%; Tissue Technologies organic growth 5.0% in Q4.
Key facts
Extracted from this filing and checked against the source text.
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
INTEGRA LIFESCIENCES HOLDINGS CORP reported Q4 2022 results: revenue $398.0 million, net income $52.9 million, EPS $0.63.
- Period
- Q4 2022
- Revenue
- $398.0 million
- Net income
- $52.9 million
- EPS
- $0.63
- Result
- reported results
Exact text from the filing
Total reported revenues for the fourth quarter were $398.0 million, a decrease of 1.8% from the fourth quarter of 2021. Fourth quarter organic revenues increased 2.9% over the prior year. The Company reported GAAP net income of $52.9 million, or $0.63 per diluted share, in the fourth quarter of 2022, compared to GAAP net income of $45.4 million, or $0.53 per diluted share, in the prior year.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
INTEGRA LIFESCIENCES HOLDINGS CORP reported FY2023 results: revenue $1,602 million to $1,620 million. Guidance initiated.
- Period
- FY2023
- Revenue
- $1,602 million to $1,620 million
- Guidance
- initiated
- Result
- guidance update
Exact text from the filing
For the full-year 2023, the Company expects revenues to be in a range of $1,602 million to $1,620 million, representing reported growth of approximately 2.9% to 4.0% and organic growth in the range of 4.0% to 5.2%.
View on SEC.gov
Earnings Releases
SEC 8-K Item 2.02
confidence 1.0
INTEGRA LIFESCIENCES HOLDINGS CORP reported FY2022 results: revenue $1,557.7 million, net income $180.6 million, EPS $2.16.
- Period
- FY2022
- Revenue
- $1,557.7 million
- Net income
- $180.6 million
- EPS
- $2.16
- Result
- reported results
Exact text from the filing
to $0.53 in the fourth quarter 2021. • Adjusted earnings per diluted share were $0.94, compared to $0.84 in the fourth quarter of 2021. Full-Year 2022 • Reported revenues were 1,557.7 million representing an increase of 1.0% on a reported basis and an increase of 4.2% on an organic basis compared to full-year 2021. • GAAP earnings per diluted share wer e $2.16,
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.